Potent Inhibition of Highly Pathogenic Influenza Virus Infection Using a Peptidomimetic Furin Inhibitor Alone Or in Combination with Conventional Antiviral Agents
Total Page：16
File Type：pdf, Size：1020Kb
Aus dem Zentrum für Hygiene und medizinische Mikrobiologie der Philipps Universität Marburg Institut für Virologie Geschäftsführender Direktor: Prof. Dr. Stephan Becker Potent inhibition of highly pathogenic influenza virus infection using a peptidomimetic furin inhibitor alone or in combination with conventional antiviral agents Dissertation Zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) dem Fachbereich Biologie der Philipps-Universität Marburg vorgelegt von Yinghui Lu aus Shanghai, China Marburg an der Lahn 2014 Die Untersuchungen zur vorliegenden Arbeit wurden im Institut für Virologie, Direktor: Prof. Dr. Stephan Becker, Fachbereich Medizin der Philipps-Universität Marburg, unter der Anleitung von Prof. Dr. Wolfgang Garten durchgeführt. Vom Fachbereich Biologie der Philipps-Universität Marburg als Dissertation angenommen am: 18.08.2014 Erstgutachter: Prof. Dr. Wolfgang Garten Zweitgutachter: Prof. Dr. Wolfgang Buckel Weitere Mitglieder der Prüfungskommission: Prof. Dr. Erhard Bremer Prof. Dr. Susanne Önel Tag der mündlichen Prüfung: 01.10.2014 献给我亲爱的家人 For my parents and sister Für meine Eltern und Schwester Inhalt Summary .................................................................................................................... 1 Zusammenfassung ..................................................................................................... 1 1. Introduction ............................................................................................................. 3 1.1 Influenza ............................................................................................................ 3 1.1.1 Classification ............................................................................................... 3 1.1.2 Clinical features and pathogenesis of influenza .......................................... 3 1.1.2.1 Human influenza viruses ...................................................................... 3 1.1.2.2 Avian influenza viruses ........................................................................ 4 1.1.2.2.1 Avian influenza H7 viruses ............................................................ 4 1.1.2.2.2 Avian influenza H5 viruses ............................................................ 6 1.1.3 Epidemiology .............................................................................................. 7 1.1.3.1 Antigenic drift and antigenic shift ......................................................... 7 1.1.3.2 History of human influenza pandemics ................................................ 8 1.1.4 Virus morphology, genome and proteins ..................................................... 9 1.1.5 Virus life cycle ........................................................................................... 12 1.2 Hemagglutinin ................................................................................................. 14 1.2.1 The structure of the hemagglutinin ............................................................ 14 1.2.2 Receptor binding specificity of hemagglutinin ........................................... 15 1.2.3 Proteolytic activation of precursor hemagglutinin ...................................... 16 1.2.3.1 Monobasic cleavage site .................................................................... 17 1.2.3.2 Multibasic cleavage site ..................................................................... 18 1.3 Proprotein convertases ................................................................................... 18 1.3.1 Furin ...................................................................................................... 19 1.4 Prevention and treatment of influenza ............................................................. 21 1.4.1 Vaccination ............................................................................................... 21 1.4.2 Approved antiviral agents .......................................................................... 22 1.4.2.1 Adamantane derivatives .................................................................... 23 1.4.2.2 Neuraminidase inhibitors ................................................................... 24 1.4.3 Other antiviral agents ................................................................................ 25 1.4.3.1 Proprotein convertase inhibitors ......................................................... 26 1.4.3.1.1 Furin inhibitors ................................................................................ 26 1.4.4 Combination therapy ................................................................................. 28 1.5 Aim of the study ............................................................................................... 29 2. Materials ............................................................................................................... 31 2.1 Chemicals ....................................................................................................... 31 2.2 Consumed materials ....................................................................................... 32 2.3 Instruments...................................................................................................... 33 2.4 Kits .................................................................................................................. 33 2.5 Protein markers ............................................................................................... 33 2.6 Antibodies ....................................................................................................... 34 2.6.1 Primary antibodies .................................................................................... 34 2.6.2 Secondary antibodies ................................................................................ 34 2.7 Enzymes ......................................................................................................... 34 2.8 Primers ............................................................................................................ 34 2.9 Viruses ............................................................................................................ 35 2.10 Consumed materials for cell cultures ............................................................ 35 2.10.1 Cell culture medium ................................................................................ 35 2.10.2 Cell lines ................................................................................................. 36 2.11 Buffers ........................................................................................................... 36 2.12 Others ........................................................................................................... 38 3. Methods ................................................................................................................ 39 3.1 Molecular and biological methods ................................................................... 39 3.1.1 Antiviral compounds .................................................................................. 39 3.1.2 MTT viability assay .................................................................................... 39 3.1.3 Stability measurements of furin inhibitors with high performance liquid chromatography ................................................................................................. 39 3.1.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis ..................... 40 3.1.5 Western blots ............................................................................................ 41 3.1.6 Viral RNA extraction .................................................................................. 41 3.1.7 One-step reverse transcription polymerase chain reaction ....................... 42 3.1.8 Two-steps reverse transcription polymerase chain reaction ..................... 43 3.1.8.1 Reverse transcription ......................................................................... 43 3.1.8.2 Polymerase chain reaction ................................................................. 43 3.1.9 DNA electrophoresis ................................................................................. 44 3.1.10 DNA fragment extraction and purification ................................................ 44 3.1.11 DNA purification ...................................................................................... 44 3.1.12 DNA-sequencing ..................................................................................... 44 3.2 Cell culture methods ........................................................................................ 45 3.3 Virological methods ......................................................................................... 45 3.3.1 Virus propagation in eggs ......................................................................... 45 3.3.2 Virus propagation in cell cultures .............................................................. 46 3.3.3 Hemagglutination assay ............................................................................ 46 3.3.4 Plaque assay ............................................................................................ 46 3.3.5 Plaque reduction assay ............................................................................. 47 3.3.6 Immunostaining ......................................................................................... 47 3.3.7 Cleavage of HA0 protein in the presence of furin inhibitors ...................... 48